Cybin to acquire Small Pharma, creating largest DMT programme
Cybin Inc. has confirmed it will acquire Small Pharma, combining to create the psychedelic industry’s largest and most advanced deuterated DMT programme. UK-based Small Pharma is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions.
The company has developed short-duration psychedelic therapies for mental health conditions, raising $63 million in capital since 2021. It has also released the first placebo-controlled efficacy results for DMT in the treatment of Major Depressive Disorder (MDD), progressing two clinical-stage DMT-based programmes, a pipeline of preclinical assets, and an IP portfolio.READ MORE